ClinicalTrials.gg
RecruitingNCT04356755ADUSEUpdated Dec 31, 2025

Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

A Phase 2 interventional study of AdMSC and Placebo in Systemic Sclerosis, sponsored by University Hospital, Toulouse. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Toulouse · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.

Planned enrollment
62nd of 81
32 · median 75
Started
2020
with 7 others
Phase 2
21 of 132
9 open now
Primary completion
2027-03
later than 16 of 47 live
Registered
71st of 132
by date

Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 62nd largest by planned enrollment of the 81 interventional ones that give a count, is one of 8 that started in 2020, is one of 21 in phase 2, reaches primary completion later than 16 of the 47 other live ones, and was the 71st registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies in Scleroderma, Systemic with a site in France, or all of them as a file.
02

Study summary

Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this phase 2 study is to compare efficacy and safety of digital injection of AdMSC versus placebo for healing refractory active ischemic digital ulcers in patients with systemic sclerosis.

Read the detailed description

Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by an autoimmune-mediated microangiopathy and progressive fibrosis. Ischemic digital ulcers (DUs) are frequent in the disease course. DUs are an expression of the severity of the microangiopathy. DUs lead to pain, infection, gangrene, autoamputation, impaired hand use and impaired quality of life. The management of DUs is often based on optimal wound care to promote healing and and repeated hospitalizations to perform onerous prostacyclin infusions to reduce pain and accelerate healing. With optimal standard of care, only 60% of DUs are healed after 3 months and 46.2% experiences recurrence during that time among them 11.2% experiences a chronic evolution. No drug has demonstrated a positive effect on refractory DUs healing. The rational underlying the use of cultured adipose-derived stromal cell (AdMSC) in this indication is based on the finding of AdMSC, in vitro and in vivo, angiogenic and anti-inflammatory potential in other ischemic pathologies, with an excellent safety profile. The pilot phase of the ACellDREAM trial demonstrated the feasibility and safety of AdMSC transplantation in patients with non- revascularizable critical limb ischemia and showed improvement in ulcer evolution and wound healing. The EFS-O culture procedure safety is validated and is already in use in ongoing French and European clinical trials. Two pilot studies showed the safety of adipose tissue grafting for scleroderma-Induced DU. The SCLERADEC pilot study outlines the safety, in 12 SSc patients, of the digital injection of adipose- derived stromal vascular fraction, which is a heterogeneous population of cells including only 36% of uncultured AdMSC. An improvement in hand disability, quality of life and DUs was observed, the phase II is ongoing. The hypothesis of the study is that digital injection of AdMSC could be efficacious for scleroderma-induced refractory ischemic DUs healing by digital vascular regeneration in a clinical situation where no alternative therapy is validated.

03

Conditions studied

  • Systemic Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient ≥18 years of age,
  • Patient with systemic sclerosis according to the 2013 ACR/EULAR classification criteria9,
  • SSc patient with at least one active ischemic digital ulcer at "inclusion visit" (see below the eligibility conditions of a DU),
  • Age > 50 years and not treated with any kind of hormone replacement therapy for at least 2 years prior to screening, with amenorrhea for at least 24 consecutive months prior to screening. An assessment of serum follicle stimulating hormone showing a level of > 40 TU/L at screening may be used to exclude , based on the discretion of the investigator,
  • Patient must have provided written prior to enrolment,
  • Patient must be able to understand their requirements of participating in the protocol,
  • Patient affiliated to a social security system.
  • Relative to each DU :

The DU at " inclusion visit " must show all the following characteristics:

  1. Located beyond the proximal interphalangeal joint, on finger surface (included periungual ulcers),
  2. Of ischemic origin according to the physician,
  3. Not over subcutaneous calcifications or bone relief,
  4. Active DU,
  5. Refractory after 10±2 weeks of standard of care according to EULAR recommendations26 (that is either still active (chronic) or new occurrence despite standard of care)

Exclusion criteria

Exclusion Criteria:

  • Current smoker or tobacco consumption stopped for less than 3 months prior to inclusion, - Patient participating in a clinical trial or having participated in a clinical trial within the previous 3 months,
  • Patients on statins, who have received treatment for less than 3 months prior to Screening or whose treatment has not been stable during this period,
  • Patients on vasodilators, such as endothelin receptor antagonists (ERAs), PDE5 inhibitors (e.g. sildenafil, tadalafil), calcium channel blockers, ACE-inhibitors, nitroglycerin, alpha adrenergic blockers, or angiotensin II receptor antagonists, N-acetylcysteine, antiplatelet aggregation therapy and low molecular weight heparin who have received treatment if present for less than 3 months prior to "inclusion visit" or whose treatment has not been stable for at least 1 month prior to "inclusion visit",
  • Treatment with disease modifying agents such as methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, Interferons and cyclophosphamide, those drugs should be stop at least 1 month prior study entry.
  • Treatment with oral (> 10 mg/day of prednisone or equivalent),
  • Systemic antibiotics (oral and TV) to treat infected DU(s) within 4 weeks prior to "inclusion visit",
  • Use of topical growth factors, hyperbaric oxygen,
  • Local injection of botulinum toxin in an affected finger within 4 weeks prior to "inclusion visit",
  • Surgical sympathectomy of the upper limbs or surgical wound debridement within 1 month prior to "inclusion visit",
  • Liposuction technically impossible,
  • Patient who underwent hematopoietic stem cell transplantation (HSCT) within less than 1 year,
  • Patients with an indication for intensification by autologous HSCT (according to EBMT guidelines and national RCP MATHEC),
  • History of cancer in the last five years, except for successfully excised basal cell/squamous cell carcinoma, or successfully excised early melanoma of the skin. Subjects, who had successfully tumor resection or radiation or chemotherapy more than 5 years from inclusion and no recurrence, may be enrolled in the study, - Subjects who have active proliferative retinopathy,
  • Positive -1 or 2, HTLV-1 or 2, or ,
  • Patients with a history of stroke, myocardial infarction or severe arrhythmia in the last 6 months
  • Patient who had severe cardiac failure in the last 6 months,
  • Females who are pregnant or breastfeeding or plan to do so during the course of this study,
  • Patient under judicial protection, - Refusal of the patient to participate in the study.
  • Relative to each DU:

    1. Digital ulcer due to conditions other than scleroderma,
    2. Non ischemic digital ulcer,
    3. Ulcers with osteomyelitis, or clinically uncontrolled infection,
    4. Infected digital ulcer requiring systemic antibiotherapy,
    5. Digital ulcer requiring urgent surgery.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    AdMSC

    Subcutaneous injections of cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma

    Drug: AdMSC

  • Placebo comparator
    Placebo

    Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma

    Drug: Placebo

Interventions

  • DrugAdMSC

    At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks

  • DrugPlacebo

    At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks

06

What researchers measure

Primary outcomes

  1. Proportion of refractory active ischemic digital ulcers healed (complete or partial)

    Partial healing is defined as \> 50% reduction of the DU area or \> 50% re epidermisation of the DU.

    Time frame: 16 weeks

  2. Composite endpoint combining healing (complete or partial) without recurrence and without local or general complications

    Partial healing is defined as \> 50% reduction of the DU area or \> 50% re epidermisation of the DU. Local complications resulting from DU worsening: * Critical ischemic crisis necessitating hospitalization, * Gangrene, (auto) amputation, * Failure of conservative management: Surgical and chemical sympathectomy, vascular reconstructions, or any unplanned surgery in the management of hand SSc manifestation(s), * Use of parenteral prostanoids after treatment injection, * Requiring class II, III or IV narcotics or increase in existing dose of \> 50 % as compared to baseline, * Initiation of systemic antibiotics for the treatment of infection attributed to digital ulceration. General complications will be assessed by: * Clinical examination * Patient reported-outcomes * Laboratory assessments

    Time frame: 16 weeks

Secondary outcomes

  1. Percentage of participants with Digital Ulcer complete healing

    Number of complete ulcer Healing. Complete healing is defined as 100% re-epidermisation.

    Time frame: 16 weeks

  2. Percentage of participants with Digital Ulcer partial healing

    Number of partial ulcer Healing. Partial healing is defined as \> 50% reduction of the DU area or \> 50% re epidermisation of the DU.

    Time frame: 16 weeks

  3. Percentage of participants with wound surface reduction <50%

    the wound surface reduction is defined by analysis photography

    Time frame: 16 weeks

  4. Percentage of participants with new Digital Ulcer

    Number of patients who do not develop any new DU.

    Time frame: 16 weeks

  5. Percentage of participants with Digital Ulcer complication

    A complication is an infection, gangrene, amputation or a DU requiring IV prostanoids.

    Time frame: 16 weeks

  6. Change from Baseline in Pain Scores

    Evaluation of pain on a Visual Analog Scale. The visual scale measures the intensity of pain on a scale ranging from 0 (no pain) to 10 (maximum pain).

    Time frame: 16 weeks

  7. Change from Baseline in severity of Raynaud's phenomenon

    Change in severity of Raynaud's phenomenon on a Visual Analog Scale. The visual scale is in a form of plastic ruler and measures the severity of Raynaud's phenomenon on a scale ranging from 0 (no pain) to 100 (maximum pain).

    Time frame: 16 weeks

  8. Change from Baseline in Digital ischaemia

    Change in digital ischaemia of the treated fingers on Digital arterial pressure.

    Time frame: 16 weeks

  9. Change from Baseline in cutaneous ischaemia

    Change in cutaneous ischaemia of the treated fingers on transcutaneous oxygen pressure (TcPO2).

    Time frame: 16 weeks

  10. Change from Baseline in Digital microvascular organisation

    Change in digital microvascular organisation of the treated fingers on nailfold capillaroscopy.

    Time frame: 16 weeks

  11. Change from Baseline in hand functional disability

    Evaluation of hand functional disability by the Cochin Hand Function Scale.

    Time frame: 16 weeks

  12. Change from Baseline in quality of life in systemic sclerosis

    Evaluation of quality of life in systemic sclerosis by scleroderma health assesment (SHAQ).

    Time frame: 16 weeks

  13. Change from Baseline in quality of life

    Evaluation of quality of life by the SF36.

    Time frame: 16 weeks

  14. Change from Baseline in health status

    Evaluation of health status by the EQ5D.

    Time frame: 16 weeks

  15. Vascular biomarkers

    Endothelin-1, Endostatin, Endogline, Angiotensin I and II, Tie 1 and 2, V-EGF, sICAM-1, sVCAM, E-selectin, CXCL4 plus anti-AT1R, anti-ETAR, anti Annexin V will be measured out in blood samples by Luminex

    Time frame: 16 weeks

07

Study locations

1 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Mar 2027, 78 months after the start.

Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 78 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2020
First posted
Apr 22, 2020
StartActual
Sep 22, 2020
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Dec 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04356755
Responsible party
Sponsor
First posted
Apr 22, 2020
Start date
Sep 22, 2020
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Dec 31, 2025

Study contacts

Grégory PUGNET, MD, PHD
Contact
pugnet.g@chu-toulouse.fr
05 61 77 71 26 ext. +33
Grégory PUGNET, MD, PHD
principal investigator

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion